Health · 32 views
STAT+: A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass
Colorado biotech Enveda reports preliminary results on a drug to help people maintain weight loss after GLP-1 use. Just don't call it exercise in a pill.
AI Summary
Enveda, a Colorado biotechnology company, released preliminary data from a phase‑one trial of a drug intended to preserve weight loss and muscle mass after patients stop using GLP‑1 agonists. The compound is described as mimicking the physiological effects of exercise, aiming to prevent the typical regain of weight and loss of lean tissue seen after GLP‑1 therapy. Early results suggest the drug may support both weight maintenance and muscle preservation, though full efficacy and safety outcomes remain to be determined.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Plague epidemic risk in Russia low after death of lab technician, WHO saysContinue reading
- Locally grown crops could expand access to childhood malnutrition treatmentContinue reading
- International consensus sets updated framework for CAR T-cell therapy in severe autoimmune diseasesContinue reading
- 'Medicare for All' message attracts midterm voters buckling under medical billsContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow